{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:35:24Z","timestamp":1789428924252,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":873,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cmi.2021.07.031","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T22:43:48Z","timestamp":1629758628000},"page":"1851-1855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"title":["Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1"],"prefix":"10.1016","volume":"27","author":[{"given":"Itzchak","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Wieder-Finesod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladyslav","family":"Litchevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Biber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Indenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liraz","family":"Olmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Huppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einav Gal","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Hod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmit","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaniv","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Rahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.07.031_bib1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2021.07.031_bib2","first-page":"100651","article-title":"Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation","volume":"29","author":"Oved","year":"2020","journal-title":"EClinMed"},{"key":"10.1016\/j.cmi.2021.07.031_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241164","article-title":"Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis","volume":"15","author":"Indenbaum","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2021.07.031_bib4","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0264-410X(97)00275-2","article-title":"Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo controlled trial","volume":"16","author":"Tasker","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.07.031_bib5","article-title":"Dynamics and significance of the antibody response to SARS-CoV-2 infection","author":"Iyer","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2021.07.031_bib6","first-page":"167","article-title":"HIV\/Influenza Vaccine Study Team. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients","volume":"39","author":"Yamanaka","year":"2005","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2021.07.031_bib7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.vaccine.2003.10.030","article-title":"Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study","volume":"22","author":"Hung","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.07.031_bib8","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/archinte.165.13.1533","article-title":"Spanish Pneumococcal Infection Study Network (G03\/103). Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy","volume":"165","author":"Grau","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2021.07.031_bib9","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.vaccine.2018.04.009","article-title":"No changes on viral load and CD4+ T-cell counts following immunization with 7-valent pneumococcal conjugate vaccine among HIV-infected adults in Malawi","volume":"36","author":"Ibraz Pavon","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2021.07.031_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jfma.2011.06.027","article-title":"Impact of vaccination with seven-valent pneumococcal conjugate vaccine on virologic and immunologic outcomes among HIV-infected adult patients in the era of highly active antiretroviral therapy","volume":"111","author":"Lu","year":"2012","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.cmi.2021.07.031_bib11","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1097\/00002030-200012010-00018","article-title":"Adult and Adolescent Spectrum of HIV Disease Investigators. Effect of influenza vaccination on disease progression among HIV-infected persons","volume":"14","author":"Sullivan","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2021.07.031_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.286.2.171","article-title":"Prevalence and predictive value of intermittent viremia with combination HIV therapy","volume":"286","author":"Havlir","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2021.07.031_bib13","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/00002030-200210180-00008","article-title":"Prevalence and clinical correlates of HIV viremia (blips) in patients with previous suppression below the limits of quantification","volume":"16","author":"Sklar","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2021.07.031_bib14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1086\/315260","article-title":"Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy","volume":"181","author":"Gunthard","year":"2000","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.031_bib15","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA based COVID-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21004237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21004237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:30:54Z","timestamp":1761118254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21004237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1198743X21004237"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.07.031","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}